BioSpace News Archive

Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.

The company will continue to analyze data regarding the secondary endpoints.

Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.

The SPAC announced it is merging with medical technology company ProKidney LP, in a deal that values the combined equity of the companies at $2.64 billion.

Gilead Sciences reported that about $250 million of counterfeit versions of its HIV drugs, Biktarvy and Descovy, were sold to pharmacies over two years.

On 25 January, Lonza Bioscience Informatics and NNIT will host a free 60-minute webinar to discuss the key requirements of next generation Manufacturing Execution Systems (MES) and how small- and medium-sized companies can overcome critical implementation challenges for accelerated pharma digitalization.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it was renaming and rebranding itself to Artivion, Inc., effective immediately.

Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and Reaffirms Financial and Operational Performance Metrics for Full Year 2022.

Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) have entered into an agreement with Cosette Pharmaceuticals, Inc. whereby Daiichi Sankyo divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the U.S.

Digital Therapeutics Alliance (“DTA” or “Alliance”), today announced the appointment of Owen McCarthy, Co-Founder & President, MedRhythms, to Chair its Board of Directors.